Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000012728 | SCV000247162 | pathogenic | Maple syrup urine disease type 2 | 2015-02-23 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV000626239 | SCV000746889 | pathogenic | Maple syrup urine disease | 2017-12-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000626239 | SCV000752992 | pathogenic | Maple syrup urine disease | 2023-11-08 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Cys26Trpfs*2) in the DBT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DBT are known to be pathogenic (PMID: 16579849, 16786533). This variant is present in population databases (rs768832921, gnomAD 0.03%). This premature translational stop signal has been observed in individuals with maple syrup urine disease (PMID: 8430702, 14517957, 16468966, 20639189, 28417071). ClinVar contains an entry for this variant (Variation ID: 11950). For these reasons, this variant has been classified as Pathogenic. |
Department Of Genetics, |
RCV004566724 | SCV000891578 | pathogenic | Maple syrup urine disease type 1A | 2024-06-12 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV000626239 | SCV001193992 | pathogenic | Maple syrup urine disease | 2019-12-24 | criteria provided, single submitter | clinical testing | NM_001918.3(DBT):c.75_76delAT(C26Wfs*2) is classified as pathogenic in the context of maple syrup urine disease type II. Sources cited for classification include the following: PMID 8430702. Classification of NM_001918.3(DBT):c.75_76delAT(C26Wfs*2) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. |
Knight Diagnostic Laboratories, |
RCV000012728 | SCV001448786 | pathogenic | Maple syrup urine disease type 2 | 2019-03-18 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000626239 | SCV002018145 | pathogenic | Maple syrup urine disease | 2021-08-16 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000626239 | SCV002033196 | pathogenic | Maple syrup urine disease | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000626239 | SCV002790945 | pathogenic | Maple syrup urine disease | 2021-08-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004566724 | SCV004190844 | pathogenic | Maple syrup urine disease type 1A | 2024-03-25 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000012728 | SCV000032963 | pathogenic | Maple syrup urine disease type 2 | 1993-02-01 | no assertion criteria provided | literature only |